Search research articles
Contact Us
Filters
Showing results (21-30 of 157) with videos related to
Page
of 16
Sort By:
International Journal of Oncology
|
March 15, 2014
The emerging role of anti-angiogenic therapy in ovarian cancer (review)
Vincenza Conteduca, Barbara Kopf, Salvatore Luca Burgio, et al.
Critical Reviews in Oncology/Hematology
|
October 24, 2024
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group
Emilio Francesco Giunta, Giandomenico Roviello, Vincenza Conteduca, et al.
European Urology Oncology
|
January 13, 2021
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer
Vincenza Conteduca, Daniel Wetterskog, Enrique Gonzalez-Billalabeitia, et al.
Cancer Treatment Reviews
|
May 19, 2024
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer
Annalisa Guida, Claudia Mosillo, Giulia Mammone, et al.
International Journal of Oncology
|
May 23, 2012
Barrett's esophagus and esophageal cancer: an overview
Vincenza Conteduca, Domenico Sansonno, Giuseppe Ingravallo, et al.
Oncotargets and Therapy
|
November 9, 2016
Cell-free DNA as a diagnostic marker for cancer: current insights
Samanta Salvi, Giorgia Gurioli, Ugo De Giorgi, et al.
Critical Reviews in Oncology/Hematology
|
October 20, 2023
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors
Brigida Anna Maiorano, Vincenza Conteduca, Martina Catalano, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
May 15, 2016
Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy
Giuseppe Schepisi, Matteo Santoni, Francesco Massari, et al.
Expert Review of Molecular Diagnostics
|
November 1, 2016
The potential use of urine cell free DNA as a marker for cancer
Samanta Salvi, Filippo Martignano, Chiara Molinari, et al.
Targeted Oncology
|
November 22, 2023
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, et al.
Page
of 16
Search research articles
Search
Showing results (21-30 of 157) with videos related to
Sort By:
Page
of 16
International Journal of Oncology
|
March 15, 2014
The emerging role of anti-angiogenic therapy in ovarian cancer (review)
Vincenza Conteduca, Barbara Kopf, Salvatore Luca Burgio, et al.
Critical Reviews in Oncology/Hematology
|
October 24, 2024
Pharmacological treatment landscape of non-metastatic hormone-sensitive prostate cancer: A narrative review on behalf of the meet-URO Group
Emilio Francesco Giunta, Giandomenico Roviello, Vincenza Conteduca, et al.
European Urology Oncology
|
January 13, 2021
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer
Vincenza Conteduca, Daniel Wetterskog, Enrique Gonzalez-Billalabeitia, et al.
Cancer Treatment Reviews
|
May 19, 2024
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer
Annalisa Guida, Claudia Mosillo, Giulia Mammone, et al.
International Journal of Oncology
|
May 23, 2012
Barrett's esophagus and esophageal cancer: an overview
Vincenza Conteduca, Domenico Sansonno, Giuseppe Ingravallo, et al.
Oncotargets and Therapy
|
November 9, 2016
Cell-free DNA as a diagnostic marker for cancer: current insights
Samanta Salvi, Giorgia Gurioli, Ugo De Giorgi, et al.
Critical Reviews in Oncology/Hematology
|
October 20, 2023
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors
Brigida Anna Maiorano, Vincenza Conteduca, Martina Catalano, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
May 15, 2016
Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy
Giuseppe Schepisi, Matteo Santoni, Francesco Massari, et al.
Expert Review of Molecular Diagnostics
|
November 1, 2016
The potential use of urine cell free DNA as a marker for cancer
Samanta Salvi, Filippo Martignano, Chiara Molinari, et al.
Targeted Oncology
|
November 22, 2023
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis
Brigida Anna Maiorano, Ugo De Giorgi, Elena Verzoni, et al.
Page
of 16